Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) – Equities researchers at Oppenheimer issued their Q1 2023 earnings estimates for Opiant Pharmaceuticals in a research report issued to clients and investors on Friday, August 12th. Oppenheimer analyst L. Gershell forecasts that the technology company will post earnings of ($1.70) per share for the quarter. The consensus estimate for Opiant Pharmaceuticals' current full-year earnings is ($6.21) per share. Oppenheimer also issued estimates for Opiant Pharmaceuticals' Q2 2023 earnings at ($1.77) EPS, Q3 2023 earnings at $0.81 EPS, Q4 2023 earnings at $1.98 EPS and FY2023 earnings at $0.58 EPS.

Separately, TheStreet lowered shares of Opiant Pharmaceuticals from a "c" rating to a "d+" rating in a research report on Tuesday, May 31st.

Opiant Pharmaceuticals Stock Performance

Insider Activity at Opiant Pharmaceuticals

In related news, Director Michael Sinclair sold 9,736 shares of the business's stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $13.88, for a total transaction of $135,135.68. Following the completion of the sale, the director now directly owns 59,484 shares in the company, valued at $825,637.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Craig A. Collard purchased 4,037 shares of the company's stock in a transaction on Monday, June 13th. The stock was acquired at an average cost of $10.94 per share, for a total transaction of $44,164.78. Following the completion of the transaction, the director now directly owns 53,822 shares in the company, valued at approximately $588,812.68. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Sinclair sold 9,736 shares of the company's stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.88, for a total transaction of $135,135.68. Following the completion of the transaction, the director now owns 59,484 shares of the company's stock, valued at $825,637.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,751 shares of company stock worth $304,412. 25.15% of the stock is owned by company insiders.

Hedge Funds Weigh In On Opiant Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Opiant Pharmaceuticals by 10.7% in the first quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company's stock worth $160,000 after buying an additional 723 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in shares of Opiant Pharmaceuticals by 2.5% in the first quarter. Essex Investment Management Co. LLC now owns 32,040 shares of the technology company's stock worth $686,000 after buying an additional 777 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of Opiant Pharmaceuticals by 4.0% in the first quarter. Parkman Healthcare Partners LLC now owns 32,557 shares of the technology company's stock worth $697,000 after buying an additional 1,266 shares in the last quarter. State Street Corp lifted its holdings in shares of Opiant Pharmaceuticals by 10.7% in the first quarter. State Street Corp now owns 13,285 shares of the technology company's stock worth $285,000 after buying an additional 1,285 shares in the last quarter. Finally, Advisor Group Holdings Inc. lifted its holdings in shares of Opiant Pharmaceuticals by 28.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 8,125 shares of the technology company's stock worth $273,000 after buying an additional 1,800 shares in the last quarter. 27.93% of the stock is currently owned by institutional investors.

About Opiant Pharmaceuticals

(Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

Featured Articles

• Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
• Here is a Simple 4 Stock Portfolio that Can Outperform the Market
• Is AMC Entertainment Pulling a Fast One on the APEs?
• Here's How the Inflation Reduction Act Energizes Power Stock
• 2 Important Retail Stock Battles to Watch
• MarketBeat: Week in Review 8/8 – 8/12

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.